The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1681
July 24, 2023
View Complete Issue         Table of Contents 2019 
Tofersen (Qalsody) for ALS
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tofersen (Qalsody) for ALS
July 24, 2023 (Issue: 1681)
Tofersen (Qalsody – Biogen), an intrathecally administered antisense oligonucleotide, has received accelerated approval from the FDA for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tofersen (Qalsody) for ALS
Article code: 1681a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.